Sitagliptin phosphate tablets are the first DPP-4 inhibitor approved for the treatment of type 2 diabetes. It can inhibit β-cell apoptosis, promote β-cell regeneration, and increase β-cells in patients with type 2 diabetes. Quantity, significantly lower the blood sugar of patients, and still have significant hypoglycemic effect on patients who have failed sulfonylureas. Sitagliptin phosphate tablets mainly achieve blood sugar control in patients with type 2 diabetes by combining exercise and diet control.
Janovi? (Sitagliptin tablets) is a potent and highly selective DPP-4 enzyme inhibitor, mainly used to improve blood sugar control in patients with type 2 diabetes. The recommended dose of this product as a single agent or in combination with metformin is 100 mg once daily.